Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 26, 2022; 10(27): 9650-9656
Published online Sep 26, 2022. doi: 10.12998/wjcc.v10.i27.9650
Published online Sep 26, 2022. doi: 10.12998/wjcc.v10.i27.9650
Efficacy of transcatheter arterial chemoembolization using pirarubicin-loaded microspheres combined with lobaplatin for primary liver cancer
Chao Zhang, Yu-Hui Dai, Liang Liu, Ting Zhao, Department of Interventional Therapy, Hebei North University Affiliated First Hospital, Zhangjiakou 075000, Hebei Province, China
Shu-Feng Lian, Zhangjiakou Qiaoxi District Maternal and Child Health Care Hospital, Zhangjiakou 075000, Hebei Province, China
Jun-Ye Wen, Department of Hepatobiliary Surgery, Hebei People’s Hospital, Shijiazhuang 050055, Hebei Province, China
Author contributions: Zhang C, Dai YH, Lian SF, Liu L, Zhao T and Wen JY designed the research study; Zhang C and Dai YH performed the research; Zhang C, Dai YH, Lian SF, Liu L, Zhao T and Wen JY analyzed the data and wrote the manuscript; All authors have read and approved the final manuscript.
Supported by Zhangjiakou Science and Technology Research and Development Program , No. 1821154H ; and Zhangjiakou Technology Innovation Guidance Program , No. 2021194H .
Institutional review board statement: The study was reviewed and approved by the Hebei North University Affiliated First Hospital Institutional Review Board.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare no conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chao Zhang, MD, Doctor, Department of Interventional Therapy, Hebei North University Affiliated First Hospital, No. 12 Changqing Road, Zhangjiakou 075000, Hebei Province, China. zcxzt2016@163.com
Received: May 16, 2022
Peer-review started: May 16, 2022
First decision: July 11, 2022
Revised: July 19, 2022
Accepted: August 16, 2022
Article in press: August 16, 2022
Published online: September 26, 2022
Peer-review started: May 16, 2022
First decision: July 11, 2022
Revised: July 19, 2022
Accepted: August 16, 2022
Article in press: August 16, 2022
Published online: September 26, 2022
Core Tip
Core Tip: Drug-eluting beads, a relatively novel drug delivery embolization system, show advantages over the conventional lipiodol embolization in the most used interventional therapy of transcatheter arterial chemoembolization for unresectable hepatic carcinoma. This study investigated the efficacy and safety of transcatheter arterial chemoembolization using pirarubicin-loaded beads combined with lobaplatin for primary liver cancer in comparison with conventional transcatheter arterial chemoembolization. The results revealed this combination therapy can increase treatment efficacy and improve hepatic function in patients with primary liver cancer.